Novartis Venture Fund investing in innovative life science companies for patient benefit, creating attractive returns for entrepreneurs and investors.
Investment Type: Venture Capital
Investment Stage: Series B
Portfolio 2
| Date | Name | Website | Total Raised | Location |
| 15.03.2023 | Mediar The... | mediartx.c... | $105M | - |
| 04.01.2018 | Oculis S.A... | oculis.com | $133.47M | Switzerlan... |
Mentions in press and media 20
| Date | Title | Description | Source |
| 16.10.2023 | AstronauTx, developing treatments for Alzheimer's, raises $5... | The startup works in partnership with UCL and is backed by Novartis and UK gov't funds In the Unite... | vator.tv/n... |
| 09.10.2023 | AstronauTx closes a £48 million ($61 million) Series A finan... | London UK, XXXX– AstronauTx Ltd. (“AstronauTx”), a biotech company developing novel treatments for A... | svhealthin... |
| 26.06.2023 | Dutch-based Tagworks Pharmaceuticals raises €59.5M to design... | The Netherlands-based Tagworks Pharmaceuticals, a company that claims to be a pioneer of Click-to-Re... | siliconcan... |
| 03.03.2023 | Oculis goes public on Nasdaq | Upon closing, Oculis had a pro-forma enterprise value of approximately $220 million and a cash bal... | startuptic... |
| 18.10.2022 | Oculis to go public via SPAC | Oculis is a global biopharmaceutical company developing treatments to save sight and improve eye c... | startuptic... |
| 02.03.2022 | London-based Epsilogen nabs £30.75 million to develop antibo... | London-based startup that develops novel immunoglobulin antibodies to treat cancer, Epsilogen has ra... | tech.eu/20... |
| 16.12.2021 | Anaveon raises CHF 110 million | Anaveon is undertaking a Phase I/II study to evaluate the safety, dosing and clinical activity of ... | startuptic... |
| 07.05.2021 | Oculis closes US$57 million Series C financing | The oversubscribed round was co-led by new investors BVCF Management and Hyfinity Investments, with ... | startuptic... |
| 07.05.2021 | Oculis closes US$57 million Series C financing | The oversubscribed round was co-led by new investors BVCF Management and Hyfinity Investments, wit... | startuptic... |
| 13.09.2019 | Anokion raises $40 million and acquires US biotech startup | The Kanyos acquisition adds KAN-101 to the portfolio, an antigen-specific treatment for celiac dis... | startuptic... |
Show more